ReviewCurrent drug targets2025
Neurostimulation for the Management of Epilepsy: Advances in Targeted Therapy.
Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpilepsy is a multifaceted neurological disorder marked by seizures that can present with a wide range of symptoms. Despite the prevalent use of anti-epileptic drugs, drug resistance and adverse effects present considerable obstacles. Despite advancements in anti-epileptic drugs (AEDs), approximately 20-30% of patients remain drug-resistant, highlighting the need for innovative therapeutic strategies.
aimThis study aimed to explore advancements in epilepsy diagnosis and treatment utilizing modern technology and medicines.
methodsThe literature survey was carried out using Scopus, ScienceDirect, and Google Scholar. Data from the last 10 years were preferred to include in the study.
resultEmerging technologies, such as artificial intelligence, gene therapy, and wearable gadgets, have transformed epilepsy care. EEG and MRI play essential roles in diagnosis, while AI aids in evaluating big datasets for more accurate seizure identification. Machine learning and artificial intelligence are increasingly integrated into diagnostic processes to enhance seizure detection and classification. Wearable technology improves patient self-monitoring and helps clinical research. Furthermore, gene treatments offer promise by treating the fundamental causes of seizure activity, while stem cell therapies give neuroprotective and regenerative advantages. Dietary interventions, including ketogenic diets, are being examined for their ability to modify neurochemical pathways implicated in epilepsy.
conclusionRecent technological and therapeutic developments provide major benefits in epilepsy assessment and treatment, with AI and wearable devices enhancing seizure detection and patient monitoring. Nonetheless, additional study is essential to ensure greater clinical application and efficacy. Future perspectives include the potential of optogenetics and advanced signal processing techniques to revolutionize treatment paradigms, emphasizing the importance of personalized medicine in epilepsy care. Overall, a comprehensive understanding of the multifaceted nature of epilepsy is essential for developing effective interventions and improving patient outcomes.
Indexed as
Identifiers
40444628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.